[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Clermont-Ferrand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":666},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,137,0,25,[9,41,75,97,127,149,178,202,225,251,278,309,334,360,388,408,443,467,489,516,543,572,602,623,645],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644263","evaluation-of-masticatory-performance-in-patients-with-periodontitis-100644263",false,"NCT07665489","Evaluation of Masticatory Performance in Patients With Periodontitis","PAROCHEW","Inclusion Criteria:\n\n* Patients followed at the university hospital (CHU) with a diagnosis of periodontitis.\n* No objection from the patient to participate in the study.\n* Patients able to speak and understand French.\n\nExclusion Criteria:\n\n* Minors.\n* Patients under legal protection (guardianship, trusteeship, or judicial protection measures).\n* Pregnant or breastfeeding women.\n* Patients who refuse to participate in the study.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The objective of this observational study is to assess the correlation between the severity of periodontal involvement and masticatory performance in patients with periodontitis.\n\nThe secondary objectives are to identify periodontal parameters that may be associated with a reduction in masticatory performance.\n\nThis study includes a single group.\n\nParticipants will be asked to perform a masticatory performance test consisting of chewing a piece of gum for 20 cycles.",[25,26,27],"Periodontitis, Adult","Periodontitis","Oral Disease","NOT_YET_RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2027-06-01",{"name":38,"class":39},"University Hospital, Clermont-Ferrand","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":40},"100645316","plant-based-diet-in-older-people-what-consequences-for-muscle-health-100645316","NCT07681986","Plant-based Diet in Older People: What Consequences for Muscle Health?","MYOVEG","Inclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n\nExclusion Criteria:\n\n* Men and women aged 65 years and older\n* Body Mass Index (BMI) between 18.5 and 30 kg\u002Fm² (exclusive)\n* Physical activity \\\u003C 3000 MET-min\u002Fweek, assessed using the ONAPS-PAQ questionnaire\n* Laboratory tests compatible with participation in the study\n* Adequate venous status, as assessed by study nurses, allowing catheter placement\n* Willingness to participate in study procedures, including indirect calorimetry, functional tests, and assigned dietary intervention (plant-enriched or standard diet)\n* Affiliation with the French Social Security system\n* Exclusion period from a previous study or total compensation exceeding €6,000 in the 12 months prior to study initiation (verified through the National Research Volunteer Database)\n* Patients under legal guardianship, curatorship, deprived of liberty, or under judicial protection\n* Claustrophobia","65 Years",{"count":50,"type":21},60,"INTERVENTIONAL",[53],"NA","This randomized, controlled, two-arm clinical study aims to determine how increasing the proportion of plant-based foods in the diet affects skeletal muscle strength, mass and function, protein metabolism, microbiota and key metabolic markers in healthy older men and women. We hypothesize that diets enriched with animal-based foods will maintain maximal quadriceps strength-the primary outcome of the study-more effectively after the 3-month nutritional intervention than plant-based diets. Proteomic analyses will be performed to identify molecular mechanisms and potential muscle biomarkers reflecting metabolic adaptations of skeletal muscle to plant-enriched diets. In addition, metabolic health markers and micronutrient status will be evaluated to better understand the overall health effects of dietary plant-based transition in older adults.",[56],"Aging",[56,58,59,60,61,62,63,64,65,66],"Older Adults","Plant-Based Diet","Muscle Strength","Skeletal Muscle","Protein Metabolism","Physical Performance","Proteomics","Body Composition","Gut Microbiota","2026-06-26",{"date":69,"type":32},"2026-07-02",{"date":71,"type":21},"2026-07-20",{"date":73,"type":21},"2030-08",{"name":38,"class":39},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":40},"100645173","study-of-the-frequency-and-characteristics-of-pain-symptoms-in-restless-legs-syndrome-100645173","NCT07679087","Study of the Frequency and Characteristics of Pain Symptoms in Restless Legs Syndrome","PAIN-RLS","Inclusion Criteria:\n\n* Male or female participants aged 18 years or older.\n* Diagnosis of Restless Legs Syndrome (RLS) according to the criteria of the International Classification of Sleep Disorders, Third Edition (ICSD-3).\n* French-speaking.\n\nExclusion Criteria:\n\n* Patient under guardianship, curatorship, or legal protection measures.\n* Patient who has never had an appointment with a neurologist as part of their SJSR care pathway.",{"count":83,"type":21},1000,"Restless Legs Syndrome (RLS) is a neurological disorder affecting between 4% and 29% of adults. It is characterized by an urge to move the legs or other parts of the body, often accompanied by unpleasant and sometimes painful sensations. The pathophysiology of RLS, whether associated with pain or not, remains poorly understood, and only a limited number of studies have specifically investigated this aspect.\n\nThe aim of this study is to determine the prevalence of the painful component of symptoms in a large cohort of patients with RLS, to further characterize its clinical features, and to assess its impact on patients' quality of life. This work could improve the identification of patients experiencing pain, enhance our understanding of pain characteristics in RLS, and help optimize patient management. Furthermore, in the context of emerging therapeutic approaches such as neuromodulation, a better characterization of pain in RLS may contribute to the development and evaluation of new treatment strategies. This is particularly relevant given the high prevalence of RLS and its substantial impact on patients' quality of life.\n\nParticipants will be recruited either through their neurologist during routine follow-up visits at the Neurology Department of Clermont-Ferrand University Hospital or through the France Ekbom Association. Individuals interested in participating will be provided with access to the online questionnaire via a QR code or a dedicated web link. One thousand patients will be include in this study (RIPH type 3). The online questionnaire is expected to take approximately 30 minutes to complete. It includes the collection of demographic data (age, sex, lifestyle factors, weight, height, employment status, comorbidities, and dietary habits), as well as questions regarding the patient's medical history and sleep habits.\n\nThe questionnaire also includes validated instruments assessing sleep, pain, RLS severity, anxiety and depression, and quality of life.\n\nAt the end of the questionnaire, participants will be invited to take part in an optional ancillary study aimed at validating the French translation of the Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL). Participants who agree to participate will complete the questionnaire once at baseline and will subsequently receive an email reminder to complete it a second time two weeks later. This test-retest procedure will be used to assess the reproducibility of the French-adapted version of the questionnaire.",[86],"RLS",[86,88,89],"Pain","Sleep","2026-06-25",{"date":31,"type":32},{"date":93,"type":21},"2026-07",{"date":95,"type":21},"2027-08",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":51,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":40},"100644014","a-study-of-the-impact-of-a-virtual-reality-medical-device-hypnovr-headset-on-anxiety-and-pain-in-interventional-radiology-100644014","NCT07668050","A Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology.","HYPNO-VR","Inclusion Criteria :\n\n* Age ≥18 years.\n* Scheduled to undergo an interventional radiology procedure performed under local anesthesia without sedation.\n* Affiliation to a health insurance system.\n* Received complete information about the study and provided written informed consent.\n* Ability to understand the study information and complete the questionnaires.\n\nExclusion Criteria :\n\n* Refusal to participate or withdrawal of consent.\n* Patients under legal protection preventing valid informed consent according to regulatory requirements.\n* Inability to understand study-related information or to use the virtual reality device due to severe visual, auditory, or cognitive impairment, as clinically assessed by the investigator.\n* History of photosensitive epilepsy or uncontrolled epilepsy, constituting a contraindication to virtual reality use.\n* Known contraindication to virtual reality use (history of severe cybersickness).",{"count":105,"type":21},70,[53],"Patients undergoing interventional radiology procedures frequently experience significant anxiety and procedural pain despite standard care. Virtual reality (VR) has emerged as a promising non-pharmacological tool for anxiety and pain reduction in various medical settings.\n\nThe HYPNO-VR study is a prospective randomized controlled trial designed to evaluate the effect of immersive virtual reality during interventional radiology procedures. Participants will be randomized in a 1:1 ratio to either a virtual reality group or a standard care control group.\n\nThe primary objective is to assess the impact of VR on procedural anxiety and pain using validated anxiety questionnaires (State-Trait Anxiety Inventory, STAI) and a numerical pain rating scale.\n\nSecondary and exploratory objectives include assessment of patient satisfaction, operator experience, procedural duration, analgesic use, and feasibility of VR integration in interventional radiology practice.",[109,88,110],"Anxiety","Radiology, Interventional",[112,113,114,115,116,117,118,119],"Virtual Reality","Interventional Radiology","State-Trait Anxiety Inventory","Patient Satisfaction","Non-pharmacological Intervention","Immersive Virtual Reality","Procedural Anxiety","Procedural Pain",{"date":121,"type":32},"2026-06-29",{"date":123,"type":21},"2026-06",{"date":125,"type":21},"2026-12",{"name":38,"class":39},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":51,"phases":136,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100644021","phase-1-fecal-transplantation-in-hidradenitis-suppurativa--a-pilot-study-100644021","NCT07668713","FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study","FESTIVAL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient with Hurley HS II (moderate severity) or III (very severe)\n* Axillomammary (LC1) or gluteal (LC3) phenotype with at least 4 inflammatory lesions: inflammatory nodule, abscess or active fistula\n* Having presented at least one relapse to a well-conducted medical treatment as proposed by the 2019 French Dermatology Society evidence center recommendations (broad-spectrum antibiotic therapy for 15 to 21 days followed by prophylactic treatment with doxycycline or cotrimoxazole). A relapse is defined as the occurrence of a new attack within 3 months of the introduction of treatment.\n\nExclusion Criteria:\n\n* Allergy or contraindication to amoxicillin-clavulanic acid\n* Patient having received biomedication in the 3 months prior to inclusion\n* Patient suffering from another inflammatory disease (IBD, inflammatory rheumatism, auto-inflammatory disease)\n* Concomitant Clostridioides Difficile infection\n* Immunocompromised patients\n* HIV infection and active HBV\u002FHCV hepatitis\n* No health insurance\n* Pregnant or breast-feeding women\n* Patients already included in a biomedical research study other than an observational study (e.g. registry, cohort)\n* Patients under guardianship\u002Fcuratorship\u002Flegal protection",{"count":135,"type":21},24,[137],"PHASE1","The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn's disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chronic inflammatory bowel disease (IBD), and is suspected in many other diseases. Fecal microbiota transplantation (FMT) is the gold-standard treatment for recurrent Clostridioides Difficile infection, and is being investigated in a wide range of conditions. Our hypothesis is that FMT would improve inflammatory lesions of HS by modifying patients' digestive microbiota.\n\nTranslated with DeepL.com (free version)",[140,141],"Hidradenitis Suppurativa (HS)","Fecal Microbiota Transplantation (FMT)","2026-06-23",{"date":90,"type":32},{"date":34,"type":21},{"date":146,"type":21},"2031-06",{"name":38,"class":39},7,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":157,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":51,"phases":160,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100643903","phase-2-functional-brain-mri-to-understand-pain-phenotypes-in-knee-osteoarthritis-100643903","NCT07668674","Functional Brain MRI to Understand Pain Phenotypes in Knee Osteoarthritis","Functional Brain MRI to Understand Pain Phenotypes in Knee Osteoarthritis: a Multicenter Comparative Pilot Study","INDIGO","Inclusion Criteria:\n\n* Women aged 40 or older (only women will be included to ensure consistency in the analyses, given the higher prevalence of osteoarthritis in women and the influence of sex\u002Fgender on the experience of pain)\n* Diagnosis of femorotibial osteoarthritis of the knee according to the 1986 American College of Rheumatology criteria\n* Presence of knee pain with an intensity of ≥ 4\u002F10 on a numerical rating scale (NRS)\n* Chronic knee pain, i.e., lasting at least 6 months with at least 15 days of pain in the past 30 days\n* Completion of the PainDETECT questionnaire, which will allow the patient to be assigned to one of two groups prior to the enrollment visit (those with nociceptive pain \\[score ≤ 12\\] and those with neuropathic pain \\[score \\> 13\\])\n* Patients have read and understood the information letter\n* Patients have signed the informed consent form\n* Patients are enrolled in a social security program\n\nExclusion Criteria:\n\n* Other joint diseases affecting the knees (gout, chondrocalcinosis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis)\n* Conditions that, in the investigator's opinion, interfere with the assessment of osteoarthritic pain, such as conditions causing neuropathic pain in the lower extremities (e.g., peripheral neuropathy, chronic radiculopathy) or fibromyalgia\n* Kellgren-Lawrence radiographic stage IV in one or both knees\n* Patients with one or more knee prostheses\n* Claustrophobia making MRI impossible\n* Contraindication to MRI\n* Pregnant or breastfeeding women\n* Patients under guardianship, conservatorship, deprived of liberty, or under judicial protection\n* Patients who have participated in an interventional clinical trial within the last 6 months that could impact the primary endpoint","FEMALE","40 Years",{"count":50,"type":21},[161],"PHASE2","Some people with knee osteoarthritis (gonarthrosis) experience pain differently. In some, the pain is described as \"nociceptive\" (directly related to the joint), while in others it has \"neuropathic\" characteristics (related to nerve function).\n\nThe goal of this multicenter, cross-sectional and comparative study is to compare resting brain activity in a brain region called the anterior insula among female patients with painful knee osteoarthritis who experience nociceptive pain compared to those with neuropathic pain.\n\nResearchers will compare brain activity at rest between these two types of pain in women over 40 with painful knee osteoarthritis. A better understanding could help improve pain management in the future.\n\nParticipants will be asked to :\n\n* complete questionnaires during the inclusion visit and on the day of the scan,\n* undergo a clinical examination and a blood test at the inclusion visit,\n* undergo a functional MRI (fMRI), an imaging test that allows observation of brain activity at rest.\n\nPaticipants in the study does not involve any additional treatment. the fMRI scan is non-invasive and does not require any injections.",[164,165],"Gonarthrosis","Neuropathic Pain, Nociceptive Pain",[164,167,168,169,170,171,155],"Neuropathic pain","Nociceptive Pain","Functional MRI","Anterior insula","Brain activity in the anterior insula at rest",{"date":90,"type":32},{"date":93,"type":21},{"date":175,"type":21},"2028-08",{"name":38,"class":39},3,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":17,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100641435","impact-of-physical-activity-during-pregnancy-on-biological-markers-at-birth-in-cord-blood-cordomouv-100641435","NCT07579468","Impact of Physical Activity During Pregnancy on Biological Markers at Birth in Cord Blood (CORDOMOUV)","CORDOMOUV","Inclusion Criteria:\n\n* Newborns born to mothers who participated in the PregMouv study (which aims to evaluate an intervention allowing women to better adhere to physical activity: program free\u002Fface-to-face\u002Fvideoconference\u002Fmixed) and born at the Clermont Ferrand University Hospital.\n\nExclusion Criteria:\n\n* If parents refuse to participate or in situations where parents are protected by law, cord blood collection cannot be done.",true,"1 Day","2 Days",{"count":189,"type":21},250,"Currently, an interventional protocol for physical activity during pregnancy is underway at the Clermont University Hospital (PREGMOUV study). In addition, we have implemented a protocol for 2 years monitoring of children birthed of this study (NEOMOUV study).\n\nRecent data from the scientific literature show that a woman's engagement in regular and appropriate physical activity during her pregnancy presents few dangers while ensuring benefits for the mother-baby dyad. Indeed, physical activity reduces maternal complications such as preeclampsia, gestational diabetes and depression and has many advantages for the child with in particular a reduction in the risk of macrosomia then obesity and diabetes.\n\nNeonatal sepsis is a major risk factor for childhood mortality. There is strong negative association between cord blood levels of calprotectin and sepsis risk in human newborns with levels of calprotectin at birth are significantly lower in infants that later experience blood-culture-proven late-onset neonatal sepsis. In adults, plasma calprotectin levels increase following acute exercise. However after 4 weeks trainging plasma calprotectin level decrease. So in response to acute exercise, plasma calprotectin levels increase but in contrast, there is a negative association between basal plasma calprotectin levels and regular physical activity. Therefore, we do not know what impact mother' regular physical activity can have on the level of calprotectin in the cord blood.\n\nThe objective of this project is to investigate the impact of physical activity during pregnancy on calprotectin value at cord blood.",[192],"New Born","RECRUITING","2026-06-18",{"date":196,"type":32},"2026-06-22",{"date":198,"type":32},"2026-05-05",{"date":200,"type":21},"2027-10",{"name":38,"class":39},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":185,"sex":157,"minAge":18,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":51,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":224,"locationsCount":40},"100598101","suppressive-functions-of-regulatory-t-cells-in-migraine-100598101","NCT07067112","Suppressive Functions of Regulatory T Cells in Migraine","SIIM-reg","Inclusion Criteria:\n\n* Females\n* 18 to 50 years old\n* Chronic migraine participants : chronic migraine (at least 15 days of headache\u002Fmonth, according to the International Classification of Headache Disorders, 3rd edition criteria\n\nExclusion Criteria:\n\n* BMI \\\u003C or = 17kg\u002Fm² or \\> or = 30kg\u002Fm²\n* Diagnosis or suspicion of type 2 diabetes, auto-immune or inflammatory diseases, immunodeficiency diseases\n* Diagnosis of headache of non-migraine origin, except for tension type headache \\\u003C or = 4 days per month (i.e.: cluster headache, post-traumatic headache, cerebral tumour…)\n* Pregnancy, delivery, miscarriage, breastfeeding, participation in a medically assisted human reproduction program (ovary stimulation\u002Fhormone therapy) \\\u003C 3 months before blood sampling\n* Menopause, hysterectomy, or bilateral oophorectomy\n* Flare of the autoimmune\u002Finflammatory disease of interest \\\u003C 1 month before blood sampling\n* Modification of maintenance therapy for the autoimmune\u002Finflammatory disease of interest (start, change of molecule, interruption) \\\u003C 3 months before blood sampling\n* Modification of prophylactic anti-migraine therapy (start, change of molecule, interruption) \\\u003C 3 months before blood sampling (for migraine participants)\n* Hormone therapy (besides contraception and treatment of endometriosis)\n* Transplantation (solid organ or bone marrow)\n* Cancer (active or remitting) \\\u003C 1 year before blood sampling (solid organ or blood)\n* Haematologic disease (benign or malignant) of the lymphoid lineage\n* Guardianship, curatorship, safeguard of justice or deprivation of liberty\n* For controls : diagnosis of migraine","50 Years",{"count":135,"type":21},[53],"Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and\u002For inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis.\n\nThe investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.",[214],"Chronic Migraine",[216,217,218,219],"Migraine","Inflammation","Immune system","Regulatory T cells",{"date":196,"type":32},{"date":31,"type":21},{"date":223,"type":21},"2027-11-30",{"name":38,"class":39},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":157,"minAge":18,"maxAge":158,"enrollmentInfo":233,"targetDuration":4,"studyType":51,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":40},"100641400","physical-activity-and-cardiometabolic-health-in-women-with-or-without-polycystic-ovary-syndrome-scopap-100641400","NCT07659392","Physical Activity and Cardiometabolic Health in Women With or Without Polycystic Ovary Syndrome (SCOPAP)","Cardiometabolic Health in Women With Overweight or Obesity, With or Without Polycystic Ovary Syndrome: Effects of a Targeted Adapted Physical Activity Program","SCOPAP","Inclusion Criteria:\n\n* Women aged 18 to 40 years (inclusive boundaries)\n* Women with a body mass index (BMI) between 25 and 40 kg\u002Fm²\n* Women performing no more than 150 minutes of moderate-to-vigorous physical activity per week\n* Women able to provide informed consent to participate\n* Women affiliated with a social security system\n* One group will consist of women with polycystic ovary syndrome, and another group will consist of women without polycystic ovary syndrome\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, as declared by the participant\n* Postmenopausal women\n* Women currently receiving pharmacological treatment for obesity or who have received such treatment within the past two years\n* Women under legal protection measures (guardianship, curatorship, or judicial protection)\n* Refusal to sign the informed consent form",{"count":234,"type":21},40,[53],"The primary objective of this study is to investigate the effects of a multidisciplinary intervention, including a targeted adapted physical activity program, on lipid oxidation during a walking exercise in women with overweight or obesity, with or without polycystic ovary syndrome. Specifically, the study aims to compare changes in lipid oxidation before and after the intervention between women with polycystic ovary syndrome and those without polycystic ovary syndrome.\n\nThe secondary objectives are to assess the impact of polycystic ovary syndrome on several physiological and metabolic parameters in women with overweight or obesity. These include: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during a walking exercise; (iv) body composition, glycemic and lipid profiles, and circulating levels of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness.\n\nIn addition, the effect of the multidisciplinary intervention, including the adapted physical activity program, will be evaluated on these same outcomes: (i) resting energy metabolism; (ii) resting blood pressure and heart rate; (iii) energy expenditure, energy cost, and heart rate during walking exercise; (iv) body composition, glycemic and lipid profiles, and concentrations of sex hormones and adipokines; (v) movement behaviors; and (vi) physical fitness, in women with overweight or obesity, with or without polycystic ovary syndrome.",[238,239],"Poly Cystic Ovary Syndrome","Overweight , Obesity",[241,242,243,244],"polycystic ovary syndrome","women","cardiometabolic","Physical activity","2026-06-16",{"date":196,"type":32},{"date":93,"type":21},{"date":249,"type":21},"2028-12",{"name":38,"class":39},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":185,"sex":17,"minAge":18,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":51,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":40},"100377774","optimization-of-a-non-invasive-electrophysiological-method-for-studying-the-functionality-of-auditory-nerve-fibers-100377774","NCT04198909","Optimization of a Non-invasive Electrophysiological Method for Studying the Functionality of Auditory Nerve Fibers","ECOG","Inclusion Criteria:\n\n* Between 18 and 55 years old\n* be affiliated to a social security system\n* understand (oral and written) of the French language\n* be a qualified hearing with normal tympanogram and audiogram\n\nExclusion Criteria:\n\n* have a complaint of hearing\n* have a exposure to noise (professional and\u002For activities)\n* refusal to participate in the study\n* have ear infections and\u002For ENT medical history\n* have cardiovascular, metabolic, neurological and psychiatric desease\n* being a protected person\n* healthy volunteer who has received compensation equal to or greader than 4500€ in clinical study","55 Years",{"count":260,"type":21},220,[53],"Acoustic overexposure can induced temporary or hearing loss. Usually hearing loss is associated with cochlear cell damages. Recently, a new pathological entity was described and called \"hidden hearing loss\". In animal model, the histopathology revealed a selective reduction in the number of auditory fibers, resulting in a decrease in the amplitude of wave I of the auditory brainstem response. Electrocochleography (Ecog) is a method for recording the electrical potentials of the cochlea (e.g. wave I). In clinical routine, Ecog is performed invasively with sedation or local anesthesia. Actually, a non invasive approach could be perform but it seems necessary to optimize this method and to define reference values in healthy volunteers.",[264,265],"Healthy Volunteer","Without Hearing Disorders",[267,268,269,270],"hidden hearing loss","questionnaire","hearing screening","electrocochleography",{"date":272,"type":32},"2026-06-17",{"date":274,"type":32},"2019-04-29",{"date":276,"type":21},"2028-04",{"name":38,"class":39},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":286,"targetDuration":4,"studyType":51,"phases":288,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":40},"100436177","job-stress-in-ophthalmology-physicians-and-residents-100436177","NCT04959838","JOB STRESS in OPHthalmology Physicians and Residents","Monitoring of JOB STRESS Related to Night Shifts in OPHthalmology Physicians and Residents","JOBSTRESS-OPH","Inclusion Criteria:\n\n* Ophthalmologists defined as physicians who completed the ophthalmology DES (Specialized studies diploma), as well as ophthalmology residents defined as a resident registered in the ophthalmology DES working during the inclusion period in the ophthalmology department of the university hospital center of Clermont-Ferrand.\n* Ability to give a written informed consent to participate in research.\n* Affiliation to a social security system.\n* Age between 18 and 65 years old\n\nExclusion Criteria:\n\n* Participant refusal to participate\n* Children under the age of 18, pregnant and breastfeeding women, protected adults (individuals under guardianship by court order), adults deprived of their liberty.",{"count":287,"type":21},30,[53],"Ophthalmology physicians and residents work under stress conditions during night emergency ophthalmology shifts. Under time pressure, that is a characteristic of the urgency of care, they must use all their cognitive resources to make an accurate diagnosis and to provide accurate decisions, with sometimes surgical emergency acts. In addition, in France, they work at night following by an usual day work, and they can also work 48 consecutive hours during weekends, followed by a work day … i.e. 60 consecutive hours of work … Long working hours with a short recovery time has been demonstrated to be a major factor of stress and fatigue. Even if not demonstrated on ophthalmologists, those working conditions may contribute to symptoms of mental exhaustion and physical fatigue (sleep deprivation), often accompanied by a loss of motivation at work. This may leads to a feeling of loss of time control; stress can also distort the perception of time and leads to hasty actions or delayed decision-making. The combined effects of stress, feelings of loss of time control, and fatigue necessarily have an impact on work performance and work quality, with a high risk of medical error. Moreover, prolonged stress may expose ophthalmologists to a higher risk of multiple diseases, predominantly systemic inflammation and coronary heart disease.\n\nThe main hypothesis is that prolonged work (up to 60 consecutive working hours) may impact on HRV, comparatively to a typical working day.",[291,292],"Stress","Heart Rate Variability",[294,295,296,297,298,299,300,301],"ophthalmologists","on-call duty","stress","surgical simulator","heart rate variability","sleep","questionnaires","actimetry","2026-06-15",{"date":245,"type":32},{"date":305,"type":32},"2021-07-06",{"date":307,"type":21},"2027-07",{"name":38,"class":39},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":51,"phases":320,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":330,"leadSponsor":332,"locationsCount":333},"100634886","odssey-scdidentification-of-markers-to-predict-the-risk-of-sudden-cardiac-death-in-moderated-lvef-in-ischemic-cardiomyopathy-100634886","NCT07545512","ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY","ODISSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY (ODISSEY-SCD","ODISSEY","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Hospitalized for acute STEMI within 6 months (Type 1 myocardial infarction according to ESC recommendations, Thygesen EHJ 2018).\n* Left ventricular ejection fraction between 35% and 50% at least 40 days after acute myocardial infarction (see above).\n* Under optimal tolerated medical treatment.\n* Covered by a social security scheme.\n* Legally competent to give voluntary informed consent to participate in the study.\n* Patient who will not participate in further studies involving an investigational drug or device until the end of the trial (i.e. 60 months). Participation in registries is authorized\n\nExclusion Criteria:\n\n* Presence of a secondary prevention indication for implantation of an implantable automatic defibrillator (ICD)\n* Presence of a pacemaker\n* Administration of ventricular antiarrhythmic drugs other than beta-blockers (i.e. amiodarone, sotalol, flecainide)\n* Patients with systemic diseases (cancer, liver failure or end-stage renal disease)\n* Patients with assessed life expectancy \\\u003C 1 year.\n* Age \\> 80\n* Adult patient under legal protection (guardianship, curatorship or other legal protection measure)\n* The subject is pregnant or nursing or positive beta HCG for women of childbearing age\n* Patient participating in another clinical research protocol involving an investigational drug or device within the last 30 days (participation in a registry is permitted at the same time).","80 Years",{"count":319,"type":21},400,[53],"Although advances in treatment and patient management have considerably improved post-infarction prognosis, the risk of sudden cardiac death remains a major concern. Sudden cardiac death (SCD) is defined as an unexpected death occurring within one hour of the onset of symptoms, often of arrhythmic origin. In patients who have survived a myocardial infarction, sudden death represents a persistent threat. This risk is often associated with complications such as left ventricular dysfunction, malignant ventricular arrhythmias, and structural alterations of the myocardium, all of which can favor the development of fatal cardiac events. Among the risk factors identified, reduced left ventricular ejection fraction, a history of ventricular arrhythmias and the presence of extensive scarring of the myocardium are particularly significant.\n\nAssessing the risk of SCD in post-infarction patients is crucial to determining appropriate prevention strategies, such as implanting automatic implantable defibrillators (ICDs). Assessment tools are varied, but currently only left ventricular ejection fraction (LVEF) \\\u003C 35% is identified and validated. However, this risk stratification is unsatisfactory, particularly in view of SCD in patients with a history of myocardial infarction and a moderately impaired LVEF (between 35 and 50%). Although the initial treatment of myocardial infarction is essential for the patient's immediate survival, managing the risk of sudden death in the long term remains a major clinical challenge. A multiparametric approach is needed to optimize prognosis and prevent premature death in these patients.",[323,324],"Myocardial Infarction (MI)","Sudden Cardiac Death Due to Cardiac Arrhythmia",[326],"Sudden cardiac death in patients with ischemic heart disease and moderately impaired left ventricular ejection fraction (between 35 and 50%).","2026-06-12",{"date":302,"type":32},{"date":31,"type":21},{"date":331,"type":21},"2033-07-01",{"name":38,"class":39},10,{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":51,"phases":345,"briefSummary":346,"conditions":347,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":40},"100622428","rhinavevaluation-of-treatments-for-acute-viral-rhinitis-rhinosinusitis-and-rhinopharyngitis-100622428","NCT07383493","RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis","RhinAV","Inclusion Criteria:\n\n* Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment,\n* Effective contraception for female patients of childbearing age.\n* Cooperation and sufficient understanding to comply with the requirements of the trial.\n* Acceptance of registration in the SI-RIPH VRB file.\n* Having received informed information and agreeing to give written consent.\n* Affiliated with the French Social Security system.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fhistory of allergy to any of the product's components,\n* Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated,\n* Chronic rhinosinusitis,\n* Allergic rhinosinusitis,\n* Other ongoing treatments for acute rhinitis (local treatment, antitussives, antibiotics, antiretrovirals, corticosteroids, etc.),\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Bacterial rhinopharyngitis with positive TROD test\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent ENT surgery (\\\u003C6 months),\n* ENT pathology such as nasal septum deviation or other causes of nasal obstruction,\n* Pulmonary pathology (COPD, asthma, etc.),\n* Immunosuppression (as reported by the patient),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).","70 Years",{"count":344,"type":21},150,[53],"The objective of this study is to conduct post-marketing clinical follow-up of four products: NS, NHE, NHG, and PIR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of acute viral rhinitis, rhinosinusitis, and rhinopharyngitis, while also assessing the benefit\u002Frisk ratio of the products.",[348,349,350,351,352,353],"Rhinitis Acute","Rhinitis Viral","Rhinosinusitis Acute","Rhinopharyngitis","Rhinitis","Rhinosinusitis",{"date":302,"type":32},{"date":356,"type":32},"2026-02-25",{"date":358,"type":21},"2027-03",{"name":38,"class":39},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":51,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":387},"100606724","veno-arterial-carbon-dioxide-partial-pressure-difference-co2gap-for-early-resuscitation-of-septic-shock-100606724","NCT07179276","Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock","Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock: A Multicenter Prospective Randomized Trial (CARBON)","CARBON","Inclusion Criteria:\n\n* Patients aged 18 years or older AND\n* Acutely admitted to a study ICU AND\n* Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as:\n\n  * A suspected or documented site of infection or positive blood culture AND\n  * Acute increase of at least 2 points in the Sequential Organ Failure Assessment (SOFA) score consequent to the infection AND\n  * Having a serum lactate level \\>2 mmol\u002Fl AND\n  * Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure (MAP) ≥65 mmHg despite adequate fluid resuscitation (at least 1L of IV fluid in the last 24 hours prior to screening)\n\nExclusion Criteria:\n\n* Septic shock for more than 12 hours at the time of screening\n* Primary cause of hypotension not due to sepsis (e.g., acute bleeding)\n* Decision not to resuscitate (or to limit full care) or not to intubate taken before obtaining consent\n* Death is deemed to be imminent or inevitable or patients with an underlying disease process with a life expectancy of less than 3 months\n* Anticipated surgery during the first 24 hours after randomization\n* Patient or their relatives' refusal to participate\n* Patients participating in another RCT with interventions possibly compromising the primary outcome\n* Prior enrollment in the CARBON trial\n* Known to be pregnant.\n* Legal protection (i.e., incompetence to provide consent and no guardian or incarceration)\n* No affiliation with the French health care system",{"count":369,"type":21},750,[53],"Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure).\n\nThe venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock.\n\nThe investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.",[373,374],"Sepsis - to Reduce Mortality in the Intensive Care Unit","Septic Shock",[376,377,378,379,380],"lactate","CO2 gap","resuscitation strategie","sepsis","hemodynamic therapy",{"date":302,"type":32},{"date":383,"type":32},"2026-03-29",{"date":385,"type":21},"2027-12-31",{"name":38,"class":39},28,{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":51,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":407,"locationsCount":40},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":396,"type":21},44,[53],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[26,400,401],"Periodontal Diseases","Quality of Life","2026-06-11",{"date":245,"type":32},{"date":34,"type":21},{"date":406,"type":21},"2028-06-01",{"name":38,"class":39},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":51,"phases":417,"briefSummary":418,"conditions":419,"keywords":427,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":442},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327","NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice",{"count":344,"type":21},[161],"The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[420,421,422,423,424,425,426],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Hodgkin Lymphoma","Lymphoma, Non-Hodgkin","Myeloma","Chronic Lymphocytic Leukemia",[428,429,430,431,432,433],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation","2026-06-08",{"date":436,"type":32},"2026-06-09",{"date":438,"type":32},"2022-12-20",{"date":440,"type":21},"2030-05",{"name":38,"class":39},20,{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":51,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":466},"100590859","evaluation-of-therapeutic-strategy-to-prevent-crohns-disease-endoscopic-postoperative-recurrence-based-on-early-dosage-of-faecal-calprotectin-100590859","NCT06972901","Evaluation of Therapeutic Strategy to Prevent Crohn's Disease Endoscopic poSToperatIve recurreNce Based on earlY Dosage of Faecal Calprotectin","DESTINY II","Inclusion Criteria:\n\n* Patients with an established diagnosis of CD according to ECCO guidelines\n* Adult Crohn's disease (age ≥ 18 years)\n* Having undergone ileal, colonic, or ileocolonic resection without residual macroscopic lesions\n* With an anastomosis that can be reached by ileocolonoscopy\n* With at least one of the following risk factors for endoscopic POR: active smoking, previous intestinal resection (before the current resection), length of resected small bowel \\> 30 cm, fistulizing phenotype (B3 according to the Montreal classification), exposure to at least two biotherapies before surgery\n* No contraindication to ustekinumab treatment\n* Patient capable of giving consent\n* Patient covered by the French healthcare system\n\nExclusion Criteria:\n\n* Permanent stoma\n* Total colectomy\n* Uncontrolled postoperative infectious complication\n* Pregnant or breastfeeding women: a pregnancy test will be performed for women of childbearing age\n* Refusal to participate in the study\n* Persons deprived of their liberty by judicial or administrative decision\n* Minors\n* Vulnerable protected adults (under guardianship, curatorship, or legal protection)",{"count":451,"type":21},42,[53],"Crohn's disease (CD) (\\> 200,000 patients in France) is a chronic inflammatory disease that can lead to progression of intestinal destruction and impaired quality of life. Despite the widespread use of biotherapies, intestinal resections remain frequent (50% of patients over time). Unfortunately, surgery is not curative since 75% of patients experienced post-endoscopic operative recurrence (POR) (i.e., recurrence of ulcerations) during the first year after surgery. Prevention of endoscopic POR (defined as a Rutgeerts index ≥ i2) is essential because endoscopic POR is highly predictive of clinical POR (i.e., recurrence of CD-related symptoms): \\> 40% and \\> 80% within 5 years for a Rutgeerts index ≥ i2 or ≥ i3, respectively. The recommended management is to start treatment after surgery to avoid endoscopic POR, and to perform a colonoscopy at 6 months (M6) with therapeutic escalation if endoscopic POR. Despite anti-TNF or ustekinumab treatment, the endoscopic POR rate remains high (30-40% at M6) leading to \\> 40% clinical POR despite therapeutic escalation (90 mg\u002F4 weeks with ustekinumab) potentially due to late therapeutic escalation. Innovative strategies are therefore needed to prevent endoscopic POR, such as the use of fecal calprotectin, a non-invasive biomarker associated with endoscopic CD activity. We have previously demonstrated that its variation between surgery and M3 allows for a value at M3 predictive of endoscopic POR at M6. In this study, we hypothesize, for the first time, that a strategy integrating fecal calprotectin measurement at M3 with earlier therapeutic escalation (M3 vs M6) in case of abnormal value or kinetics could decrease the rate of endoscopic POR at M6.",[455,456,457],"Crohn Disease (CD)","Ileocolic Resection","Post-endoscopic Operative Reccurence","2026-06-03",{"date":460,"type":32},"2026-06-05",{"date":462,"type":32},"2025-10-13",{"date":464,"type":21},"2027-03-01",{"name":38,"class":39},8,{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":476,"conditions":477,"keywords":478,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":40},"100638901","efficacy-of-anti-il-6-treatments-on-migraine-in-patients-treated-with-anti-il-6-for-a-rheumatological-condition-100638901","NCT07598045","Efficacy of Anti-IL-6 Treatments on Migraine in Patients Treated With Anti-IL-6 for a Rheumatological Condition","RHUMIL-6","Inclusion Criteria (for screening) :\n\n* at least 18 years old\n* ongoing or previous anti-IL-6 (anti-IL-6 group) or anti-TNF (anti-TNF group) therapy, taken for at least 3 months\n\nInclusion Criteria (patients to be enrolled) : migrainous patients, identified using the International Classification of Headache Disorders, version 3 (ICHD-3) criteria from the International Headache Society (IHS) during the telephone call\n\nExclusion Criteria:\n\n* Biotherapy treatment in the context of a diagnosis of giant cell arteritis\n* Verbal communication not possible\n* No affiliation to the French national health insurance system, legal protection measure (guardianship, curatorship, judicial protection)",{"count":475,"type":21},320,"Migraine affects approximately 15% of the global population. Its prevalence doubles or even triples in individuals with chronic inflammatory conditions, such as chronic inflammatory rheumatic diseases (34%), multiple sclerosis (MS) (46%), or endometriosis (35%). The prevalence of chronic migraine - defined as at least 15 headache days per month (on average over the past 3 months), of which at least 8 days have migrainous features - is also higher in certain conditions such as MS (4%) compared to the general population (1%). The mechanisms underlying migraine and its chronification remain uncertain, but inflammation appears to play an important role in its pathophysiology: it is present from the onset of a migraine attack, represented by the release of pro-inflammatory cytokines that sensitize the trigeminal system and promote the occurrence of new attacks. The investigators' recent bibliographic work has demonstrated elevated levels of interleukin-6 (IL-6), a pro-inflammatory cytokine, in the blood of episodic migraine patients between attacks (migrainous status) compared to non-migrainous subjects, and in chronic migraine patients compared to episodic migraine patients (chronic migraine status). IL-6 appears to play a role in the pathophysiology of migraine, and elevated levels may represent a marker of poorer response to prophylactic treatments. IL-6 levels are also elevated in inflammatory rheumatic diseases and are associated with disease severity. The efficacy of IL-6 pathway-blocking treatments in inflammatory rheumatic diseases is now well established, and these agents are commonly used for this indication. IL-6 could therefore represent a shared pathophysiological link between migraine and inflammatory rheumatic diseases. However, no study to date has measured the effect of IL-6-blocking treatments on migraine. This study therefore aims to assess the effect of anti-IL-6 treatments on migraine in migrainous patients followed in the rheumatology department of the Clermont-Ferrand University Hospital and treated with anti-IL-6 therapy for their rheumatological condition (rheumatoid arthritis, polymyalgia rheumatica, etc.). It will provide preliminary results regarding the effect of anti-IL-6 agents on migraine and could justify future therapeutic studies.",[216],[216,217,479,480],"Anti-IL-6 therapy","Chronic inflammatory rheumatic diseases","2026-06-02",{"date":483,"type":32},"2026-06-04",{"date":485,"type":21},"2026-05-26",{"date":487,"type":21},"2027-05-26",{"name":38,"class":39},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":51,"phases":499,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":40},"100554332","benefit-of-hypnosis-on-pain-during-stitches-in-emergency-room-100554332","NCT06497712","BEnefit of HYpnosis on Pain During Stitches in Emergency Room","BEnefit of HYpnosis on Pain During Stitches in Emergency Room: The BE-HYPER Study","BE-HYPER","Inclusion criteria\n\n* Age \\> 18 years old\n* Admitted in the emergency department of Clermont-Ferrand University Hospital\n* Stitchable wound\n* Patient's agreement\n\nExclusion criteria\n\n* Pregnancy\n* Breast feeding\n* Refusal to participate\n* Patient not able to participate\n* Patients under guardianship, curatorship, deprived of liberty or safeguard of justice.\n* History of cardiac rhythm disorders (atrial fibrillation, pacemaker)\n* Psychotic disorder\n* Age \\\u003C 18 years old\n* Surgery needed\n* Patients who don't speak French\n* Wound of the eyelids, nose, ears or mouth\n* Deaf patients\n* Patients without a social security coverage\n* Nitrous oxyde use\n* Substance abuse\n* Head trauma with GSC ≤ 14\n* Patient with endocrine diseases on the cortisol axis",{"count":498,"type":21},180,[53],"Suturing is a daily practice in the emergency department, but it can be painful and stressful for patients. Hypnosis is increasingly used as a complement to the usual painkillers. The aim of our study was to investigate the impact of hypnosis on stitch placement in emergency department patients presenting with lacerations assessed by heart rate variability.",[502],"Wound of Skin",[504,505,506,507,508],"hypnosis","wound","stitches","pain","sinusal variability of cardiac frequency","2026-05-29",{"date":481,"type":32},{"date":512,"type":32},"2025-05-15",{"date":514,"type":21},"2028-05-15",{"name":38,"class":39},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":157,"minAge":18,"maxAge":258,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":526,"conditions":527,"keywords":530,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":542},"100560297","thrombinography-in-pregnant-woman-and-in-vitro-action-of-low-molecular-weight-heparin-100560297","NCT06575309","THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin","Longitudinal Study of the in Vitro Action of Low Molecular Weight Heparin (LMWH) in Pregnant Women by Thrombinography","TROPHE","Inclusion Criteria:\n\n* Normal 1st trimester pregnancy\n* Age \\> 18\n\nExclusion Criteria:\n\n* Coagulation disease (Von Willebrand disease, known coagulation factor deficiency before pregnancy)\n* VTE history\n* First-degree family history of idiopathic VTE\n* Known biological risk factor for thrombosis Inherited deficiencies in coagulation inhibitors (antithrombin, protein C, protein S) Factor V Leiden polymorphism Prothrombin gene 20210G\\>A polymorphism Anti-phospholipid antibodies\n* Current anticoagulant use (VKA, heparins, etc.)\n* Gestational diabetes detected in the 1st trimester\n* Pre-existing type 1 and type 2 diabetes\n* History of pathological pregnancy Premature delivery Postpartum hemorrhage Preeclampsia\n* Hepatopathy\n* Obesity (BMI ≥ 30)\n* Infections (HIV, HBV, HCV...)\n* Autoimmune diseases\n* Pregnancy resulting from in vitro fertilization protocol\n* Multiple pregnancy\n* Patient under guardianship, curatorship or safeguard of justice\n* Patient not covered by a social security scheme\n* Patient deprived of liberty",{"count":525,"type":21},50,"Pregnancy is associated with major changes affecting all satges of hemostasis. Certain procoagulant factors are increased, such as factors VII, VIII, IX, X, XII, fibrinogen and Von Willebrand factor. Anticoagulant molecules are also affected by pregnancy, notably the protein C - protein S (PC - PS) system. overall, PC activity is little affected by pregnancy, increasing in the 2nd trimester and decreasing in the 3rd, but remaining within normal values. PS decreases from the first trimester of pregnancy, then progressively with gestational age. Antithrombin is stable during pregnancy.\n\nThe increased in most coagulation factors, combined with the decrease in concentrations of anticoagulant molecules, creates a state of relative hypercoagulability that protects women from bleeding during homostatic challenge of childbirth, but predisposes them to venous thromboembolic events.\n\nThe risk of venous thromboembolism (VTE) during pregnancy is increased compared to non-pregnant women of the same age. The post-partum period is also considered a thrombotic risk state for up to 12 weeks after delivery. Data on the incidence of VTE as a function of gestational age are contradictory: depending on the study, incidence may be stable or increase with advancing pregnancy.\n\nLow-molecular-weight heparin (LMWH) is the anticoagulant treatment of choice for prophylactic or curative treatment of VTE during pregnancy.\n\nPhysiological changes during pregnancy may alter the pharmacokinetic properties of LMWH. The increased volume of distribution and higher glomerular filtration rate may result in a reduced anticoagulant effect. On the other hand, the state of hypercoagulability probably counteracts the anticoagulant effect of LMWH. Nevertheless, the need to adjust doses during pregnancy remains controversial, and monitoring of anti-Xa activity is not clearly recommended. The optimal dose of LMWH in pregnant women, for both preventive and curative treatment, remains poorly understood. Initiation of treatment with LMWH therefore requires discussion of the dosage to be administered.\n\nAssessment of anticoagulation using more precise tools than those currently available on a routine basis could be useful in this context.\n\nThrombinography enables the amount of thrombin generated in the presence of coagulation activators to be assessed over time. This tool can be used to assess the impact of in vitro addition of different doses of LMWH in pregnant versus non-pregnant women and in the postpartum period.\n\nIn this pilot study, the investigators propose to evaluate thrombin generation, before and after in vitro addition of LMWH, in pregnant women longitudinally, during the 3 trimesters of pregnancy, postpartum and post-pregnancy.",[528,529],"Pregnant Women","Venous Thromboembolic Disease",[531,532,533,534],"Thrombography","Pregnancy","Postpartum","Low molecular weight heparins (LMWH)","2026-05-28",{"date":509,"type":32},{"date":538,"type":32},"2024-11-22",{"date":540,"type":21},"2027-12",{"name":38,"class":39},2,{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":553,"conditions":554,"keywords":557,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":569,"leadSponsor":571,"locationsCount":40},"100637240","french-cross-cultural-adaptation-of-the-iowa-infant-feeding-attitude-scale-iifas-100637240","NCT07620704","French Cross-cultural Adaptation of the Iowa Infant Feeding Attitude Scale (IIFAS)","French Cross-cultural Adaptation of the Iowa Infant Feeding Attitude Scale (IIFAS) and Assessments of Parental Representations of Infant Feeding During Pregnancy in the Auvergne Perinatal Network.","FRENCH IIFAS","Part 1\n\nInclusion Criteria:\n\n* Adult women hospitalized for postpartum care in one of the 10 maternity hospitals of the Auvergne perinatal network participating in the project, and\u002For adult co-parents whose partner is hospitalized in one of the 10 RSPA maternity hospitals participating in the project,\n* Mothers and\u002For co-parents of a singleton child born alive at term (≥37 weeks' gestation) and hospitalized in the maternity ward,\n* Mothers and\u002For co-parents of a child less than 6 days old,\n* Mothers and\u002For co-parents affiliated to a social security scheme,\n* Mothers and\u002For co-parents capable of reading and understanding French.\n\nNon-inclusion Criteria:\n\n* Mothers and\u002For co-parents of a child hospitalized outside the maternity ward,\n* Mothers and\u002For co-parents who are adults with legal incapacity (under guardianship, conservatorship, or judicial protection),\n* Mothers and\u002For co-parents who refuse to participate in the study,\n* Mothers with a contraindication to AM and\u002For co-parents whose spouse has a contraindication to AM,\n* Mothers and\u002For co-parents of a child with a medical condition or malformation that affects their feeding.\n\nPart 2 during 1st trimester :\n\nInclusion Criteria:\n\n* Pregnant adult women who are being cared for by healthcare professional belonging the Auvergne perinatal network and\u002For their co-parents of legal age, during the first trimester of pregnancy (before 16 weeks and 0 days of gestation),\n* Pregnant women and\u002For co-parents affiliated to a social security scheme,\n* Pregnant women and\u002For co-parents who can read and understand French.\n\nNon-inclusion criteria :\n\n* Pregnant women and\u002For co-parents in the second trimester of pregnancy (between 16 weeks 0 days and 28 weeks 6 days of gestation),\n* Pregnant women and\u002For co-parents who are legally incapacitated adults (under guardianship, conservatorship, or judicial protection),\n* Pregnant women and\u002For co-parents who refuse to participate in the study,\n* Pregnant women with a contraindication to breastfeeding and\u002For co-parents whose partner has a contraindication to breastfeeding,\n* Pregnant women with a multiple pregnancy and\u002For co-parents being monitored for a multiple pregnancy.\n\nPart 2 during 3rd trimester :\n\nInclusion Criteria:\n\n* Pregnant adult women who are being cared for by healthcare professional belonging the Auvergne perinatal network and\u002For their co-parents of legal age, during the third trimester of pregnancy (after 28 weeks and 6 days of gestation),\n* Pregnant women and\u002For co-parents affiliated to a social security scheme,\n* Pregnant women and\u002For co-parents who can read and understand French.\n\nNon-inclusion criteria :\n\n* Pregnant women and\u002For co-parents in the second trimester of pregnancy (between 16 weeks 0 days and 28 weeks 6 days of gestation),\n* Pregnant women and\u002For co-parents who are legally incapacitated adults (under guardianship, conservatorship, or judicial protection),\n* Pregnant women and\u002For co-parents who refuse to participate in the study,\n* Pregnant women with a contraindication to breastfeeding and\u002For co-parents whose partner has a contraindication to breastfeeding,\n* Women and\u002For co-parents of a child with a medical condition or malformation affecting the child's feeding,\n* Pregnant women with a multiple pregnancy and\u002For co-parents being monitored for a multiple pregnancy.",{"count":552,"type":21},930,"Our study will consist of two parts:\n\n* Part 1: Cross-cultural adaptation of the Iowa Infant Feeding Attitude Scale (IIFAS) among postpartum mothers and co-parents in France and assessment of its psychometric properties\n* Part 2: Assessment of cultural representations of infant feeding practices during pregnancy.\n\nThe goal of this repeated cross-sectional study is to cross-culturally adapt and evaluate the psychometric properties of the French version of the IIFAS among postpartum mothers in France.\n\nIn the part 1 of the study, the main questions it aims to answer are:\n\n* Evaluation of the psychometric properties of the French version of the Iowa Infant Feeding Attitude Scale (IIFAS) among postpartum mothers in France\n* Evaluation of the psychometric properties of the French version of the Iowa Infant Feeding Attitude Scale (IIFAS) among postpartum co-parents in France\n\nParticipants will be asked :\n\n* to complete the study questionnaires, including the French version of the IIFAS questionnaire.\n* to complete the French version of the IIFAS questionnaire a second time 7 days after their initial completion.\n* to answer 1 to 4 questions about the infant's current feeding regimen 8 weeks after giving birth.\n\nIn the part 2, the goal of this descriptive cross-sectional study is to assess cultural representations of infant feeding practices during pregnancy among pregnant women in France during the first and the third trimesters.\n\nIn the part 2 of the study, the main questions it aims to answer are:\n\n* To describe cultural perceptions of infant feeding practices among mothers in France during the first and third trimesters of pregnancy.\n* To describe the cultural perceptions of infant feeding practices among co-parents in France during the first and third trimesters of pregnancy.\n* To compare the cultural perceptions of infant feeding practices among mothers according to the trimester of pregnancy.\n* To analyze the impact of different factors (age, education level, occupation, number of children, geographic origin, socioeconomic status, having been breastfed oneself, having personal experience with breastfeeding, plans to return to work, etc.) on mothers' cultural perceptions of infant feeding practices during the first and third trimesters of pregnancy.\n* To compare co-parents' cultural perceptions of infant feeding methods according to the trimester of pregnancy.\n* To analyze the impact of different factors (age, education level, occupation, number of children, geographic origin, socioeconomic status, having been breastfed oneself, having a child who was previously breastfed, etc.) on co-parents' cultural perceptions of infant feeding methods during the first and third trimesters of pregnancy.\n* To compare the cultural perceptions of infant feeding practices between mothers and co-parents during the first and third trimesters of pregnancy.\n\nParticipants will be asked to complete the study questionnaires, including the French version of the IIFAS questionnaire.",[555,556],"Parents of Healthy Newborns","Pregnant Women and Partners",[558,559,560,561,562,563,564,565],"Mother","parents","breastfeeding","infant formula","choice","social representation","Cross-cultural adaptation","validation study","2026-05-27",{"date":481,"type":32},{"date":566,"type":21},{"date":570,"type":21},"2029-01-27",{"name":38,"class":39},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":342,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":51,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":287},"100608759","phase-2-phase-ii-study-evaluating-safety-and-efficacy-of-tislelizumab-for-elderly-patients-unfit-for-chemotherapy-with-advanced-esophageal-squamous-cell-carcinoma-100608759","NCT07205731","Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","PRODIGE 102 - FFCD 2201 - SAFE-ESO Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","SAFE ESO","Inclusion Criteria:\n\n* Histologically proven esophageal squamous cell carcinoma (ESCC)\n* Metastatic or locally advanced cancer\n* Absence of previous treatment (immunotherapy, chemotherapy or radiotherapy) in first line setting\n* Ineligibility for a platinum-based chemotherapy assessed by oncologist and geriatrician\n* At least one evaluable and\u002For measurable lesion as defined by RECIST v1.1 criteria\n* Patients ≥ 70 years\n* Subjects with WHO performance status ≤ 2\n* Estimated life expectancy \\>3 months\n* Adjuvant therapy finished \\>6 months\n* Adequate marrow and organ functions defined as:\n\n  * Absolute neutrophil count (ANC) ≥ 1 × 109\u002FL,\n  * Platelet count ≥ 75 × 109\u002FL,\n  * Hemoglobin ≥ 90 g\u002FL,\n  * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN, or AST and ALT ≤5 ×ULN for patients with liver metastases\n  * ALP ≤ 5 x ULN unless liver metastases are present, in which case it must be ≤ 10x ULN\n  * Measured creatinine clearance (CL) \\> 40 mL\u002Fmin (MDRD method)\n* Male patients must use a condom during treatment and for 6 months after the last dose when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential during treatment and for 6 months after the last dose.\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations including follow up.\n* Signed written informed consent obtained prior to any study specific procedures\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* History of another primary malignancy. May be included, patients with:\n\n  * Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of treatment\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease\n  * Adequately treated carcinoma in situ without evidence of disease\n* Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator\n* Participation in another clinical study with an investigational product during the last 2 months.\n* Concurrent enrolment in another clinical study unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.\n* History of allogenic organ, bone marrow, or double umbilical cord blood transplantation\n* Active documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). May be included:\n\n  * Patients with vitiligo or alopecia\n  * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.\n  * Any chronic skin condition that does not require systemic therapy.\n  * Patients with celiac disease controlled by diet alone\n* Previous immune checkpoint inhibitor therapy within the 2 years before inclusion\n* Uncontrolled intercurrent illness; uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention (recurrence ≤ 14 days after intervention). Patients with the following diseases are not excluded and may proceed to further screening:\n\n  * Controlled Type I diabetes\n  * Hypothyroidism (provided it is managed with hormone replacement therapy only)\n  * Controlled celiac disease\n  * Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, alopecia)\n  * Any other disease that is not expected to recur in the absence of external triggering factors\n* Patients with evidence of fistula (either oesophageal\u002Fbronchial or oesophageal\u002Faorta)\n* Patients considered at poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled ventricular arrhythmia, recent (within 6 months) myocardial infarction, pulmonary embolism\u002Fdeep vein thrombosis, cerebrovascular accident, and heart failure, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, interstitial bilateral lung disease on high Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent. Underlying medical conditions (including laboratory abnormalities) or alcohol or drug abuse or dependence that will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or AEs or might impair compliance with study conduct. A history of severe hypersensitivity reactions to other monoclonal antibodies. Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc) or any investigational therapies within 14 days or 5 half-lives (whichever is shorter) of the first study drug administration.\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukaemia or with features suggestive of MDS\u002FAML.\n* Patient with symptomatic central nervous system (CNS) metastases.\n* History of active primary immunodeficiency.\n* Known non-controlled serologically positive human immunodeficiency virus (HIV) patients with CD4 \\\u003C 400 \u002F mm3.\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), active untreated hepatitis B (known positive HBV surface antigen (HBsAg) result), active untreated hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of -immunotherapy. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n  * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* Receipt of live attenuated vaccine within 30 days prior to the first dose of ICI\n* Follow-up impossible, according to investigator's decision\n* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol or follow-up schedule\n* Persons i) deprived of liberty by judicial or administrative decision, persons subject to psychiatric care under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8 and persons admitted to a health or social care facility for purposes other than research, and (ii) adults subject to a legal protection measure or unable to express their consent (Article L1121-8)",{"count":581,"type":21},95,[161],"The goal of this clinical trial is to assess the percentage of patients alive at 6 months in elderly patients, not eligible to an platinum-based chemotherapy, but who can received the Tislelizumab treatment alone as first-line treatment for an advanced esophageal squamous-cell carcinoma (ESCC).\n\nTislelizumab is a monoclonal antibody administred by intravenous infusion\n\nThis study aims to anwer too at the questions:\n\n* the Safety of the drug\n* Overall survival (OS) at 6 months according the diagnostic of PD-L1 expression (PD-L1 is a protein present on the surface of immune cells)\n* Overall response rate (ORR) according to imagery criteria\n* Progression-free survival (PFS) at 3 and 6 months according to imagery criteria and depending on PDL1 expression\n* Patients' health-related quality of life\n* OS and PFS according to geriatric parameters\n* Prognostic value of immune biomarkers",[585],"Esophageal Squamous Cell Carcinoma (ESCC)",[587,588,589,590,591,592,593],"digestive oncology","immunotherapy","microenvironment biomarker","oncology","oncogeriatric domain","Ederly patients","chemotherapy","2026-05-18",{"date":596,"type":32},"2026-05-20",{"date":598,"type":32},"2025-10-07",{"date":600,"type":21},"2030-10",{"name":38,"class":39},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":609,"targetDuration":4,"studyType":51,"phases":611,"briefSummary":613,"conditions":614,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":617,"startDateStruct":619,"completionDateStruct":620,"leadSponsor":622,"locationsCount":40},"100639162","phase-4-first-lines-of-biologics-in-patients-with-ulcerative-colitis-a-randomised-controlled-trial-100639162","NCT07576452","FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial","STARTER","Inclusion Criteria:\n\n* Male or female patients (using effective contraception and a negative pregnancy test for women of childbearing age) diagnosed with UC for at least 3 months\n* Age ≥ 18 years and ≤ 65 years\n* Moderate to severe UC according to modified Mayo score (from 5 to 9)\n* With endoscopic Mayo score ≥ 2\n* With an inadequate response, failure, loss of response, or intolerance to 5-ASA, steroids, or immunosuppressants.\n* Patient capable of giving consent\n* Patient covered by the French healthcare system\n* Women of childbearing age using active contraception (contraceptive implant, oral contraception, female condom or abstinence)) for at least the duration of the study\n\nExclusion Criteria:\n\n* Usual contra-indication to infliximab, filgotinib, vedolizumab or ustekinumab\n* Steroids \\> 20 mg\u002Fday within two weeks before inclusion\n* Low proctitis (disease limited to the rectum with an extent \\\u003C 5 cm)\n* Prior history of thromboembolism events\n* Prior history of major cardiovascular problems (such as heart attack or stroke)\n* Long-standing smokers (\\> 40 pack years)\n* Crohn's disease\n* Stoma or colectomy\n* Prior exposure to anti-TNF agents, anti-integrins, anti-interleukines 12 and 23 or JAK inhibitor\n* Prior exposure to other biologics or experimental drug\n* No health insurance\n* Pregnant or lactating women : a pregnancy test will be performed for women of childbearing age\n* Patients already included in biomedical research other than an observational study (e.g: registry, cohort)\n* Concomitant Clostridioides difficile infection\n* HIV infection\n* Patient who does not master the French language\n* Patient under guardianship, curatorship or safeguard of justice\n* Minors",{"count":610,"type":21},240,[612],"PHASE4","Ulcerative colitis (UC) is a chronic bowel disease. It causes inflammation of the rectum and sometimes the colon. This disease can also affect other parts of the body. It can be very difficult to live with on a daily basis. People with UC may experience frequent diarrhea, rectal bleeding, urgency to defecate, and even incontinence. All of this can significantly reduce their quality of life.\n\nThe goal of treatment is twofold:\n\n* To eliminate or reduce symptoms (this is clinical remission),\n* To allow the bowel to heal.\n\nWhen these two goals are achieved, the risk of relapse, hospitalization, surgery, or colorectal cancer decreases.\n\nTo monitor the progression of the disease, gastroenterologists use a test called fecal calprotectin: this is a protein measured in stool that helps detect intestinal inflammation.\n\nWhen conventional treatments like corticosteroids or immunosuppressants are ineffective or poorly tolerated, the investigators use more targeted therapies.\n\nFor a long time, doctors have used drugs called anti-TNFs. They block a protein responsible for inflammation (TNF-alpha). These treatments are often injected under the skin, which is generally well-tolerated by patients.\n\nA drug called infliximab, now available as a subcutaneous injection, could be used as a first-line treatment for ulcerative colitis because it appears to be more effective than other injectable anti-TNFs.\n\nAnother drug, vedolizumab, works differently from anti-TNFs and can also be used as a first-line treatment.\n\nMore recently, new classes of drugs have shown promise:\n\n* JAK inhibitors (such as filgotinib),\n* interleukin-12 and interleukin-23 inhibitors (such as ustekinumab).\n\nThese new treatments have advantages, such as the oral administration method for filgotinib and the fact that they can be used alone, without any other associated medication, which could simplify patients' lives and improve their quality of life.\n\nToday, there are increasingly more different treatments for ulcerative colitis, and the investigators still don't know clearly what the best strategy is:\n\nIs it better to start with one type of medication rather than another? Does the order in which the investigators try treatments lead to different results?\n\nThis is an important question for gastroenterologists, as their goal is to choose the most appropriate treatment for each patient from the outset.\n\nThe main objective of this research is to compare four strategies, corresponding to four treatment arms, starting with the use of infliximab, filgotinib, vedolizumab, or ustekinumab, to maintain remission in patients with ulcerative colitis.\n\nThe following four arms are therefore proposed:\n\n* Based on efficacy: infliximab - filgotinib - ustekinumab - vedolizumab\n* Based on safety: ustekinumab - vedolizumab - infliximab - filgotinib\n* Based on current practice: vedolizumab - infliximab - filgotinib - ustekinumab\n* Based on convenience and route of administration: filgotinib - ustekinumab - vedolizumab - infliximab\n\nThis study will also allow for a comparison of the efficacy, safety, participant acceptability, and quality of life of the four treatment regimens.\n\nThis study is intended for adult patients (aged 18 to 65), male or female, with moderate or severe ulcerative colitis (UC) for at least 3 months. Treatment for these patients must require biologic therapy, as determined by the investigator. Participants must be able to provide informed consent to participate in the research and must be covered by a national health insurance plan. Women of childbearing age must be using active contraception for at least the duration of the study (2 years).\n\nPatients will be followed for two years. They will be seen at the initial visit, then every two months during the first year, and then every three months during the second year. At each visit, they will be required to undergo blood and stool tests and complete a questionnaire. Endoscopies will be scheduled for weeks 16, 52, and 104. Patient treatments can be optimized once, and based on the endoscopic score, patients may change treatments according to a predefined sequence.",[615],"Ulcerative Colitis (UC)","2026-05-11",{"date":618,"type":32},"2026-05-13",{"date":34,"type":21},{"date":621,"type":21},"2030-12-01",{"name":38,"class":39},{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":185,"sex":157,"minAge":209,"maxAge":4,"enrollmentInfo":630,"targetDuration":4,"studyType":51,"phases":632,"briefSummary":633,"conditions":634,"keywords":636,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":616,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":40},"100595265","resting-state-imaging-and-osteoporosis-100595265","NCT07030205","Resting-state Imaging and OSteoporosiS","ROSS","Inclusion Criteria (patients):\n\n* Women aged 50 or over, with postmenopausal osteoporosis, fractured or not, diagnosed by their rheumatologist,\n* Able to give informed consent to participate in the research,\n* Affiliation with the French Social Security.\n\nInclusion Criteria (healthy volunteers):\n\n* Women aged 50 or over,\n* Bone densitometry performed as part of the protocol, not suggestive of osteoporosis and validated by investigators,\n* Matched to patients by age, menopausal status, socio-educational level and manual laterality,\n* Able to give informed consent to participate in the research,\n* Affiliation with the French Social Security.\n* Registration or acceptance of registration in the national register of volunteers participating in Research.\n\nExclusion Criteria (patient and healthy volunteers):\n\n* Presence of pacemaker,\n* Presence of medical devices (implants or prostheses),\n* Incompatibility of the patient with the safety criteria of the medical imaging center for carrying out magnetic resonance experiments at 3 Tesla,\n* Contraindications to the realization of MRI without injection such as claustrophobia proven, hearing aid, pacemaker wearers, wearing a brain clip,\n* Refusal to be informed in the event of the accidental discovery of an anomaly during the resting state functional magnetic resonance imaging,\n* Woman under legal protection or deprived of liberty,\n* Refusal to participation",{"count":631,"type":21},66,[53],"This study will be conducted in 20 postmenopausal healthy volunteers, 20 postmenopausal osteoporotic patients with fracture and 20 postmenopausal osteoporotic women without fracture, in order to compare functional connectivity between brain areas. Participants will complete different questionnaires and tests assessing cognition, quality of life, sleep, physical activity, pain, anxiety and depression. A biological sample will be performed in order to evaluate different markers of bone remodeling. A Resting-state functional magnetic resonance imaging (rs-fMRI) will be realized in order to establish functional connectivity between brain regions.",[635],"Osteoporosis",[635,637,638],"Resting state fMRI (rs-fMRI)","Cognition",{"date":618,"type":32},{"date":641,"type":32},"2025-09-03",{"date":643,"type":21},"2027-12-01",{"name":38,"class":39},{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":649,"acronym":650,"eligibilityCriteria":651,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":342,"enrollmentInfo":652,"targetDuration":4,"studyType":51,"phases":654,"briefSummary":655,"conditions":656,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":40},"100636765","evaluation-of-treatments-for-sore-throat-associated-with-acute-pharyngitis-andor-viral-tonsillitis-100636765","NCT07569939","Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and\u002For Viral Tonsillitis","PharyTol","Inclusion Criteria:\n\n* Pharyngitis or tonsillitis or acute nasopharyngitis or viral-origin sore throat with odynophagia that began less than 72 hours before the inclusion visit according to the investigator's judgment\n* Bacterial rhinopharyngitis with negative TROD test\n* Effective contraception for female patients of childbearing age\n* Cooperation and sufficient understanding to comply with the requirements of the trial\n* Acceptance of registration in the SI-RIPH database\n* Having received informed information and agreeing to give written consent\n* Affiliated with the French Social Security scheme.\n\nExclusion Criteria:\n\n* Hypersensitivity\u002Fprevious allergy to any of the product components,\n* Pharyngitis or tonsillitis or acute rhinopharyngitis complicated (phlegmon, acute otitis media, pneumonia…) or severely intolerable cough,\n* Positive antigen test for influenza A\u002FB or COVID-19 and infection requiring etiological treatment according to the recommendations,\n* Other ongoing treatments for acute pharyngitis or tonsillitis (local treatment, antibiotics, corticosteroids, antiretroviral…),\n* Comorbidities or health conditions deemed incompatible with the trial by the investigator,\n* Recent otorhinolaryngology surgery (\\\u003C6 months),\n* Pulmonary pathology (Chronic Obstructive Pulmonary Disease, asthma…),\n* Immunosuppression (according to patient's report),\n* Pregnant or breastfeeding women,\n* Currently participating in another clinical trial, or in the exclusion period, or having received total compensation of more than €6,000 in the 12 months prior to the start of the trial,\n* Benefiting from legal protection measures (guardianship, trusteeship, deprivation of liberty, judicial protection).",{"count":653,"type":21},160,[53],"The objective of this study is to conduct post-marketing clinical follow-up of four products: HMG, PHN, PHR, and TUR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of sore throats related to acute pharyngitis and\u002For viral-origin tonsillitis, while also assessing the benefit\u002Frisk ratio of the products.",[657,658],"Acute Pharyngitis","Viral Sore Throat","2026-05-06",{"date":616,"type":32},{"date":662,"type":21},"2026-05",{"date":664,"type":21},"2028-01",{"name":38,"class":39},""]